Revolution Medicines, Inc. (RVMD) is a publicly traded company in the Unknown sector. Across all available filings, 29 corporate insiders have executed 532 transactions totaling $365.3M, demonstrating a bearish sentiment with -$216.3M in net insider flow. The most recent transaction on Feb 6, 2026 involved a transaction of 24,010 shares valued at $0.
No significant insider buying has been recorded for RVMD in the recent period.
No significant insider selling has been recorded for RVMD in the recent period.
Based on recent SEC filings, insider sentiment for RVMD is bearish with an Insider Alignment Score of 20/100 and a net flow of -$216.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Revolution Medicines, Inc. (RVMD) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 29 insiders are actively trading RVMD stock, having executed 532 transactions in the past 90 days. The most active insider is Peter Svennilson (Executive), who has made 26 transactions totaling $84.2M.
Get notified when executives and directors at RVMD file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | A. Goldsmith Mark | Executive | Option Exercise | 24,010 | $N/A | $0 | |
| Feb 6, 2026 | A. Goldsmith Mark | Executive | Option Exercise | 24,010 | $0.54 | $13.0K | |
| Jan 21, 2026 | Cislini Jeff | General Counsel | Sale | 908 | $115.60 | $105.0K | |
| Jan 7, 2026 | Anders Jack | Chief Financial Officer | Option Exercise | 10,000 | $N/A | $0 | C-Suite |
| Jan 7, 2026 | Anders Jack | Chief Financial Officer | Sale | 10,000 | $98.00 | $980.0K | C-SuiteLarge |
| Jan 7, 2026 | Anders Jack | Chief Financial Officer | Option Exercise | 10,000 | $42.45 | $424.5K | C-Suite |
| Dec 16, 2025 | Anders Jack | Executive | Sale | 3,104 | $77.09 | $239.3K | |
| Dec 16, 2025 | A. Horn Margaret | Executive | Sale | 4,847 | $76.82 | $372.3K | |
| Dec 16, 2025 | Michael Kelsey Stephen | Executive | Sale | 5,447 | $76.82 | $418.4K | |
| Dec 16, 2025 | A. Goldsmith Mark | Executive | Sale | 15,394 | $76.82 | $1.2M | Large |
| Dec 16, 2025 | Cislini Jeff | Executive | Sale | 2,688 | $76.82 | $206.5K | |
| Nov 25, 2025 | A. Goldsmith Mark | Executive | Sale | 3,000 | $75.00 | $225.0K | |
| Nov 25, 2025 | A. Goldsmith Mark | Executive | Sale | 3,000 | $75.00 | $225.0K | |
| Nov 25, 2025 | A. Goldsmith Mark | Executive | Sale | 60,000 | $75.08 | $4.5M | Large |
| Nov 25, 2025 | A. Goldsmith Mark | Executive | Option Exercise | 60,000 | $4.09 | $245.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 286 | $290.8M | 78.4% |
Purchase(P) | 38 | $74.5M | 20.1% |
Exercise(M) | 109 | $5.4M | 1.5% |
Disposition(D) | 1 | $81.1K | 0.0% |
Gift(G) | 5 | $0 | 0.0% |
Award(A) | 71 | $0 | 0.0% |
Other(J) | 14 | $0 | 0.0% |
Conversion(C) | 8 | $0 | 0.0% |
Insider selling pressure at Revolution Medicines, Inc. has increased, with 29 insiders executing 532 transactions across all time. Total sales of $290.8M significantly outpace purchases of $74.5M, resulting in a net outflow of $216.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.